Claim Missing Document
Check
Articles

Found 13 Documents
Search

Tinjauan Imunologi pada Fenomena Non-Responder terhadap Vaksinasi Hepatitis B: Analisis Arjana, Adika Zhulhi; Devita, Ninda
Cermin Dunia Kedokteran Vol 52 No 4 (2025): Kedokteran Umum
Publisher : PT Kalbe Farma Tbk.

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.55175/cdk.v52i4.1437

Abstract

Hepatitis B vaccine has been highly effective in preventing HBV infection. However, a subset of individuals fails to develop adequate protective antibodies after complete vaccination series (anti-HBs ≥ 10 mIU/mL), termed as non-responders. Non-responder phenomenon is influenced by a complex interplay of genetic, immunological, and environmental factors. This narrative review aims to delve into the immunological aspects of the non-responder phenomenon, exploring the factors influencing vaccine response, the immunological mechanisms involved, and potential approaches to managing and overcoming non-responders.
Clinical application of dendrimer in cancer and COVID-19 therapy: a review Devita, Ninda; Nurfadilah; Siti Khadijah; Ulil Albab Habibah
Indonesian Journal of Pharmacology and Therapy Vol 5 No 2 (2024)
Publisher : Faculty of Medicine, Public Health, and Nursing Universitas Gadjah Mada and Indonesian Pharmacologist Association or Ikatan Farmakologi Indonesia (IKAFARI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.22146/ijpther.2311

Abstract

Dendrimers are nanoparticles with unique characteristics. These characteristics allow these nanoparticles to be widely applied in medicine. It can be used as a therapy for various types of cancer. The dendrimers can also been use an alternative to accelerating the diagnosis and therapy of COVID-19. This review aimed to delve deeper into the myriad clinical applications of dendrimers in the treatment of various cancers and its potential use for the treatment or diagnosis of COVID-19. The databases used for this review were Google Scholar and Science Direct. The inclusion criteria for this review are articles published in 2018-2023. Articles other than the original articles and reviews we excluded from the study. Anticancer formulated in dendrimers have a better ability to eradicate cancer cells in the treatment of breast, colon, lung, prostate, skin, ovarian, and liver cancers compared to ordinary anticancer agents. Dendrimer in vivo, in vitro and phase II clinical trials can be used to deliver miRNA therapy or symptomatic drugs in COVID-19 patients and as vaccine delivery agents. The quality of molecular diagnosis of COVID-19 can also be improved with these nanoparticles. The use of dendrimers can improve the quality of management of cancer and COVID-19 patients.
Post-hajj acute respiratory infections: Proportion and associated factors pilgrims from an Indonesian hajj guidance group Devita, Ninda; Rachmawaty, Farida Juliantina; Andriyanto, Eko; Muhammad, Afivudien
JKKI : Jurnal Kedokteran dan Kesehatan Indonesia JKKI, Vol 17, No 1, (2026)
Publisher : Faculty of Medicine, Universitas Islam Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20885/JKKI.Vol17.Iss1.art7

Abstract

Background: The Hajj pilgrimage is the largest mass gathering, posing a high risk of acute respiratory infection (ARI) transmission. Post-Hajj ARI represents a major public health concern, as returning pilgrims may serve as carriers and potentially transmit pathogens to their home communities. Identifying the proportion and risk factors of post-Hajj ARI is essential for developing effective preventive strategies.Objectives: This study aimed to determine the proportion of post-Hajj ARI and associated risk factors among pilgrims from KBIHU (Indonesian hajj and umrah guidance group) Multazam Ad-Dakwah Yogyakarta 2025.Methods: This cross-sectional study used an online questionnaire. Respondents were pilgrims from KBIHU Multazam Ad-Dakwah Yogyakarta who experienced ARI symptoms after the 2025 Hajj. Sociodemographic characteristics, vaccination history, preventive behaviors, and metabolic risk factors were collected. Data were analyzed using multivariate logistic regression. Odd ratios with 95% CIs were calculated. P-values <0.05 were considered statistically significant.Result: In total, 112 pilgrims were included. Of these, 20.5% were aged 60 years or older. More than half (57.1%) reported comorbidities, mainly hypertension and dyslipidemia. Most participants were non-smokers (82.1%). They reported moderate adherence to preventive behaviors, including mask use (54.5%) and hand hygiene (56.3%). Meningococcal vaccination coverage was universal. Coverage for influenza (75.0%), COVID-19 (46.4%), and pneumococcal vaccination (6.3%) was lower. Overall, 100 pilgrims (89.3%) experienced ARI symptoms. Bivariate analysis showed that age over 60 years was significantly associated with ARI (cOR 4.697; 95%CI: 1.206–18.295; p=0.026). Multivariate logistic regression confirmed that older age was the only significant determinant of ARI (aOR 4.88; 95% CI: 1.22–19.53; p=0.02).Conclusion: Age 60 or over is a significant risk factor for post-Hajj ARI. Focused preventive strategies targeting elderly pilgrims are essential to reduce ARI-related morbidity and mortality after the Hajj.